Regeneron (REGN) Q2 EPS Jumps 53%
(NASDAQ:REGN), a leading biotechnology firm known for its work in immunology and ophthalmology, reported Q2 2025 earnings on August 1, 2025. The headline news: the company posted Non-GAAP earnings per share of $12.89, towering nearly 52.9% above the non-GAAP consensus estimate of $8.43. Reported GAAP revenue hit $3.68 billion, also ahead of the projected $3.29 billion (GAAP), and up 3.6% year-over-year. This performance was set against ongoing manufacturing and regulatory hurdles, particularly in its retinal disease portfolio, but momentum from collaboration and immunology therapies continued to drive results. Overall, the quarter reflected financial strength and operational discipline, though some key segments faced headwinds.
Source: Analyst estimates for the quarter provided by FactSet.
Regeneron develops, manufactures, and markets medicines for serious diseases with a primary focus on immunology, ophthalmology, oncology, and rare conditions. Its scientific model centers on a robust pipeline, powered by technologies that accelerate the creation of new treatments for conditions with unmet medical needs.
Source Fool.com
Regeneron Pharmaceuticals Inc. Stock
The stock is an absolute favorite of our community with 44 Buy predictions and no Sell predictions.
With a target price of 730 € there is a slightly positive potential of 5.4% for Regeneron Pharmaceuticals Inc. compared to the current price of 692.6 €.
